View Item 

Show simple item record

Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients
dc.contributor.authorBrook, Robert D.
dc.contributor.authorKaciroti, Niko
dc.contributor.authorBakris, George
dc.contributor.authorDahlöf, Björn
dc.contributor.authorPitt, Bertram
dc.contributor.authorVelazquez, Eric
dc.contributor.authorWeber, Michael
dc.contributor.authorZappe, Dion H.
dc.contributor.authorHau, Tsushung
dc.contributor.authorJamerson, Kenneth A.
dc.date.accessioned2018-03-07T18:25:32Z
dc.date.available2019-03-01T21:00:18Zen
dc.date.issued2018-01
dc.identifier.citationBrook, Robert D.; Kaciroti, Niko; Bakris, George; Dahlöf, Bjxörn ; Pitt, Bertram; Velazquez, Eric; Weber, Michael; Zappe, Dion H.; Hau, Tsushung; Jamerson, Kenneth A. (2018). "Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients." Journal of the American Heart Association (1): n/a-n/a.
dc.identifier.issn2047-9980
dc.identifier.issn2047-9980
dc.identifier.urihttps://hdl.handle.net/2027.42/142520
dc.publisherWiley Periodicals, Inc.
dc.subject.otherhypertension
dc.subject.otherblood pressure
dc.subject.othertherapy
dc.subject.otherrisk
dc.subject.othercardiovascular disease
dc.titlePrior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142520/1/jah32856_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142520/2/jah32856.pdf
dc.identifier.sourceJournal of the American Heart Association
dc.identifier.citedreferenceMancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31: 1281 – 1357.
dc.identifier.citedreferenceZanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circ Res. 2015; 116: 1058 – 1073.
dc.identifier.citedreferenceWeber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlöf B, Kelly RY, Hua TA, Hester A, Pitt B; ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010; 56: 77 – 85.
dc.identifier.citedreferenceBakris G, Briasoulis A, Dahlof B, Jamerson K, Weber MA, Kelly RY, Hester A, Hua T, Zappe D, Pitt B; ACCOMPLISH Investigators. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high‐risk patients with hypertension and coronary artery disease. Am J Cardiol. 2013; 112: 255 – 259.
dc.identifier.citedreferenceJamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high‐risk patients. N Engl J Med. 2008; 359: 2417 – 2428.
dc.identifier.citedreferenceBrook RD, Weder AB. Initial hypertension treatment: one combination fits most? J Am Soc Hypertens. 2011; 5: 66 – 75.
dc.identifier.citedreferenceJames PA, Oparil S, Carter BL, Cushman WC, Dennison‐Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 Evidence‐based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311: 507 – 520.
dc.identifier.citedreferenceSPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood‐pressure control. N Engl J Med. 2015; 373: 2103 – 2116.
dc.identifier.citedreferenceZanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, Laragh JH, Plat F, Battegay E, Calvo‐Vargas C, Cieslinski A, Degaute JP, Holwerda NJ, Kobalava J, Pedersen OL, Rudyatmoko FP, Siampooulos KC, Sotset O. Outcomes in subgroups of hypertensive patients treated with regimens based upon valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006; 24: 2163 – 2168.
dc.identifier.citedreferenceGradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension. 2013; 61: 309 – 318.
dc.identifier.citedreferenceEgan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu‐Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012; 59: 1124 – 1131.
dc.identifier.citedreferenceBrown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel‐group trial. Lancet. 2011; 377: 312 – 320.
dc.identifier.citedreferenceFeldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009; 53: 646 – 653.
dc.identifier.citedreferenceJamerson KA, Bakris GL, Weber MA. 24‐Hour ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med. 2010; 363: 98.
dc.identifier.citedreferenceBakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos‐Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial Investigators. Renal outcomes with different fixed‐dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010; 375: 1173 – 1181.
dc.identifier.citedreferenceGradman AH, Basile JN, Carter BL, Bakris GL; American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens. 2010; 4: 42 – 50.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jah32856_am.pdf
Size:
383.8KB
Format:
PDF
View/Open
Name:
jah32856.pdf
Size:
446.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.